These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29480831)

  • 1. Adherence and virologic outcomes among treatment-naïve veteran patients with human immunodeficiency virus type 1 infection.
    Cheng Y; Sauer B; Zhang Y; Nickman NA; Jamjian C; Stevens V; LaFleur J
    Medicine (Baltimore); 2018 Jan; 97(2):e9430. PubMed ID: 29480831
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A marginal structural model to estimate the causal effect of antidepressant medication treatment on viral suppression among homeless and marginally housed persons with HIV.
    Tsai AC; Weiser SD; Petersen ML; Ragland K; Kushel MB; Bangsberg DR
    Arch Gen Psychiatry; 2010 Dec; 67(12):1282-90. PubMed ID: 21135328
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antiretroviral Adherence Level Necessary for HIV Viral Suppression Using Real-World Data.
    Byrd KK; Hou JG; Hazen R; Kirkham H; Suzuki S; Clay PG; Bush T; Camp NM; Weidle PJ; Delpino A;
    J Acquir Immune Defic Syndr; 2019 Nov; 82(3):245-251. PubMed ID: 31343455
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Pill Burden on Adherence, Risk of Hospitalization, and Viral Suppression in Patients with HIV Infection and AIDS Receiving Antiretroviral Therapy.
    Scott Sutton S; Magagnoli J; Hardin JW
    Pharmacotherapy; 2016 Apr; 36(4):385-401. PubMed ID: 26923931
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Odds of Viral Suppression by Single-Tablet Regimens, Multiple-Tablet Regimens, and Adherence Level in HIV/AIDS Patients Receiving Antiretroviral Therapy.
    Sutton SS; Magagnoli J; Hardin JW
    Pharmacotherapy; 2017 Feb; 37(2):204-213. PubMed ID: 28028855
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adherence to nonnucleoside reverse transcriptase inhibitor-based HIV therapy and virologic outcomes.
    Nachega JB; Hislop M; Dowdy DW; Chaisson RE; Regensberg L; Maartens G
    Ann Intern Med; 2007 Apr; 146(8):564-73. PubMed ID: 17438315
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Study of the impact of HIV genotypic drug resistance testing on therapy efficacy.
    Van Vaerenbergh K
    Verh K Acad Geneeskd Belg; 2001; 63(5):447-73. PubMed ID: 11813503
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improving adherence and clinical outcomes through an HIV pharmacist's interventions.
    Ma A; Chen DM; Chau FM; Saberi P
    AIDS Care; 2010 Oct; 22(10):1189-94. PubMed ID: 20640958
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of gender and calendar year on time to and duration of virologic suppression among antiretroviral-naïve HIV-infected individuals initiating combination antiretroviral therapy.
    Raboud J; Blitz S; Walmsley S; Thompson C; Rourke SB; Loutfy MR;
    HIV Clin Trials; 2010; 11(6):340-50. PubMed ID: 21239362
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Adherence and viral suppression among infants and young children initiating protease inhibitor-based antiretroviral therapy.
    Teasdale CA; Abrams EJ; Coovadia A; Strehlau R; Martens L; Kuhn L
    Pediatr Infect Dis J; 2013 May; 32(5):489-94. PubMed ID: 23249913
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Integrase inhibitor-based regimens result in more rapid virologic suppression rates among treatment-naïve human immunodeficiency virus-infected patients compared to non-nucleoside and protease inhibitor-based regimens in a real-world clinical setting: A retrospective cohort study.
    Jacobson K; Ogbuagu O
    Medicine (Baltimore); 2018 Oct; 97(43):e13016. PubMed ID: 30412140
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Risk factors for short-term virologic outcomes among HIV-infected patients undergoing regimen switch of combination antiretroviral therapy.
    Chao C; Tang B; Hurley L; Silverberg MJ; Towner W; Preciado M; Horberg M
    AIDS Res Hum Retroviruses; 2012 Dec; 28(12):1630-6. PubMed ID: 22475276
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics associated with virologic failure in high-risk HIV-positive participants with prior failure: a post hoc analysis of ACTG 5251.
    Robbins GK; Cohn SE; Harrison LJ; Smeaton L; Moran L; Rusin D; Dehlinger M; Flynn T; Lammert S; Wu AW; Safren SA; Reynolds NR
    HIV Clin Trials; 2016 Jul; 17(4):165-72. PubMed ID: 27347650
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Adherence and virologic suppression during the first 24 weeks on antiretroviral therapy among women in Johannesburg, South Africa - a prospective cohort study.
    El-Khatib Z; Ekstrom AM; Coovadia A; Abrams EJ; Petzold M; Katzenstein D; Morris L; Kuhn L
    BMC Public Health; 2011 Feb; 11():88. PubMed ID: 21303548
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Does short-term virologic failure translate to clinical events in antiretroviral-naïve patients initiating antiretroviral therapy in clinical practice?
    ; Mugavero MJ; May M; Harris R; Saag MS; Costagliola D; Egger M; Phillips A; Günthard HF; Dabis F; Hogg R; de Wolf F; Fatkenheuer G; Gill MJ; Justice A; D'Arminio Monforte A; Lampe F; Miró JM; Staszewski S; Sterne JA
    AIDS; 2008 Nov; 22(18):2481-92. PubMed ID: 19005271
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Patient and Facility Correlates of Racial Differences in Viral Control for Black and White Veterans with HIV Infection in the Veterans Administration.
    Vaughan Sarrazin MS; Ohl ME; Richardson KK; Asch SM; Gifford AL; Bokhour BG
    AIDS Patient Care STDS; 2018 Mar; 32(3):84-91. PubMed ID: 29620926
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of HIV Virologic Failure Rates Between Patients with Variable Adherence to Three Antiretroviral Regimen Types.
    Gordon LL; Gharibian D; Chong K; Chun H
    AIDS Patient Care STDS; 2015 Jul; 29(7):384-8. PubMed ID: 26114665
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Association between prescription cost sharing and adherence to initial combination antiretroviral therapy in commercially insured antiretroviral-naïve patients with HIV.
    Johnston SS; Juday T; Seekins D; Espindle D; Chu BC
    J Manag Care Pharm; 2012 Mar; 18(2):129-45. PubMed ID: 22380472
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antiretroviral therapy and efficacy after virologic failure on first-line boosted protease inhibitor regimens.
    Zheng Y; Hughes MD; Lockman S; Benson CA; Hosseinipour MC; Campbell TB; Gulick RM; Daar ES; Sax PE; Riddler SA; Haubrich R; Salata RA; Currier JS
    Clin Infect Dis; 2014 Sep; 59(6):888-96. PubMed ID: 24842909
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Duration of Antiretroviral Therapy Adherence Interruption Is Associated With Risk of Virologic Rebound as Determined by Real-Time Adherence Monitoring in Rural Uganda.
    Haberer JE; Musinguzi N; Boum Y; Siedner MJ; Mocello AR; Hunt PW; Martin JN; Bangsberg DR
    J Acquir Immune Defic Syndr; 2015 Dec; 70(4):386-92. PubMed ID: 26110445
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.